Yotaro Tamai

Kamakura, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

Feasibility of Salvage Therapy With High-Dose Bendamustine and Rituximab Based on a Series of Two Cases From a Planned Phase II Trial for Relapsed/Refractory Diffuse Large B-cell Lymphoma.

Feasibility of Salvage Therapy With High-Dose Bendamustine and Rituximab Based on a Series of Two Cases From a Planned Phase II Trial for Relapsed/Refractory Diffuse Large B-cell Lymphoma.

Journal: Cureus

Published: January 29, 2026

Efficacy and safety of romiplostim with horse anti-thymocyte globulin and cyclosporine in acquired aplastic anemia.

Efficacy and safety of romiplostim with horse anti-thymocyte globulin and cyclosporine in acquired aplastic anemia.

Journal: International journal of hematology

Published: September 25, 2025

Outcome of initial cord blood transplantation with FM80TBI as conditioning regimen for acute myeloid leukemia.

Outcome of initial cord blood transplantation with FM80TBI as conditioning regimen for acute myeloid leukemia.

Journal: Annals of hematology

Published: July 05, 2025

Dose-Attenuated-Polatuzumab Vedotine plus CHP vs. Dose-Attenuated -R-CHOP in Patients Aged ≥ 80 Years with Diffuse Large B-Cell Lymphoma: A Retrospective, Propensity Score-Matched Analysis Stratified by Simplified Frailty Score.

Dose-Attenuated-Polatuzumab Vedotine plus CHP vs. Dose-Attenuated -R-CHOP in Patients Aged ≥ 80 Years with Diffuse Large B-Cell Lymphoma: A Retrospective, Propensity Score-Matched Analysis Stratified by Simplified Frailty Score.

Journal: Mediterranean journal of hematology and infectious diseases

Published: July 05, 2025

Efficacy and safety of romiplostim in aplastic anemia refractory or intolerant to immunosuppressive therapy with eltrombopag

Efficacy and safety of romiplostim in aplastic anemia refractory or intolerant to immunosuppressive therapy with eltrombopag

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: March 05, 2025

Retrospective analysis of treatment discontinuation in minimal residual disease negative multiple myeloma.

Retrospective analysis of treatment discontinuation in minimal residual disease negative multiple myeloma.

Journal: International journal of hematology

Published: January 09, 2025

Preconditioning intervention prior to allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.

Preconditioning intervention prior to allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.

Journal: Experimental hematology

Published: December 05, 2024

Real-world effectiveness and safety of rituximab and reduced-dose CHP with polatuzumab vedotin (pola-R-CHP) in patients aged > 80 years with diffuse large B-cell lymphoma: a retrospective analysis.

Real-world effectiveness and safety of rituximab and reduced-dose CHP with polatuzumab vedotin (pola-R-CHP) in patients aged > 80 years with diffuse large B-cell lymphoma: a retrospective analysis.

Journal: Blood research

Published: November 17, 2024

Pathophysiology, Treatment, and Prognosis of Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Failure, and Organomegaly (TAFRO) Syndrome: A Review.

Pathophysiology, Treatment, and Prognosis of Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Failure, and Organomegaly (TAFRO) Syndrome: A Review.

Journal: Current issues in molecular biology

Published: July 18, 2024

Successful treatment of two cases with Philadelphia-chromosome positive acute lymphoblastic leukemia who relapsed after allogeneic stem cell transplantation and the treatments with novel immunotherapies and ponatinib.

Successful treatment of two cases with Philadelphia-chromosome positive acute lymphoblastic leukemia who relapsed after allogeneic stem cell transplantation and the treatments with novel immunotherapies and ponatinib.

Journal: Hematology (Amsterdam, Netherlands)

Published: June 03, 2024

A phase 2 clinical trial of luspatercept in non-transfusion-dependent patients with myelodysplastic syndromes.

A phase 2 clinical trial of luspatercept in non-transfusion-dependent patients with myelodysplastic syndromes.

Journal: International journal of hematology

Published: May 09, 2024

WT1-guided pre-emptive therapy after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.

WT1-guided pre-emptive therapy after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.

Journal: International journal of hematology

Published: February 27, 2024

Showing 1-12 of 50

Last Updated: 09/26/2026